

Our mission

Together with our clinicians, we develop unique patient blood management solutions for improved patient and stakeholder benefits.

Our publications



Combined Platelet and Red Blood Cell Recovery during On-pump Cardiac Surgery Using same™ by i-SEP Autotransfusion Device: A First-in-human Noncomparative Study (i-TRANSEP Study).



Combined Platelet and Erythrocyte Salvage: Evaluation of a New Filtration-based Autotransfusion Device.




A novel transfusion device saving erythrocytes and platelets used in a 72h survival swine model of surgically induced controlled blood loss.

Our device: same™



Intuitive usage and short set up: 2 min.

Ordering information



same™ system

DS1000

Pre-assembled treatment kit

ST0501M1 (5 kits)

Suction & anticoagulation line	XJ-13-05 (24 pcs)
Blood collection reservoir	XJ-28-18 (6 pcs)
Vacuum line	LE0000M1 (30 pcs)

Additional references:

Reinfusion bag	BE1000M1 (25 pcs)
Waste bag	BW1000M1 (15 pcs)
Micro-aggregate chamber	LF0000M1 (25 pcs)

Contact us

+49 2161 4966835

mail@allforperfusion.de

www.allforperfusion.de

D-COM-021EN-V1.0



same™

Restore your patient's RBCs and platelets in 6 minutes

i-SEP



“**Our own blood is still the best thing to have in our veins**”¹

42.2% patients receive perioperative blood transfusions in cardiac surgical procedures²

Allogenic transfusions save but:

- **60%** are considered as inappropriate³
- **15-year longer life expectancy** for non-transfused cardiac surgery patients¹
- **Platelet transfusion** is linked to many significant risks⁴

30% patients not transfused due to blood shortage⁵

1. WHO 2021, The urgent need of implementing patient blood management.
 2. Perioperative transfusion and long-term mortality after cardiac surgery : a meta-analysis. Woldendorp K. et al. March 2023.
 3. Appropriateness of Allogeneic Red Blood Cell Transfusion: The International Consensus Conference on Transfusion Outcomes. Shander A. et al. July 2011.
 4. Platelet transfusion: Alloimmunization and refractoriness. Prodger CF. et al. April 2020.
 5. EFS, French National Blood Bank Report, February 2022.

A **new** approach to your transfusion strategy

same™ technology is recommended for hemorrhagic-risk surgery.

- Patented innovation
- Unique filtration technology
- Unprecedented platelet recovery
- Cycles aligned with surgical time: 6 min/500 mL*





86%
Red blood cells recovered



52%
Platelets recovered




84%
Platelet functionality



Benefits & safety for patients***

- Improve patient blood management
- Save platelets, including for patients not transfused due to blood product shortage
- Reduce overall allogenic transfusion



*In-vitro study. **Overdevest, 2012; Garg, 2015; Lindau, 2018; Serrick, 2003; i-SEP clinical study, 2021. *** Poster NATA April 2024.